Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Synthesis and Biological Studies of New Multifunctional Curcumin Platforms for Anticancer Drug Delivery.

Bazylevich A, Tuchinsky H, Zigman-Hoffman E, Weissman R, Shpilberg O, Hershkovitz-Rokah O, Patsenker L, Gellerman G.

Med Chem. 2019;15(5):537-549. doi: 10.2174/1573406415666181203112220.

PMID:
30501600
2.

18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).

Bernstine H, Domachevsky L, Nidam M, Goldberg N, Abadi-Korek I, Shpilberg O, Groshar D.

Medicine (Baltimore). 2018 Apr;97(16):e0490. doi: 10.1097/MD.0000000000010490.

3.

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.

Kalimuthu K, Lubin BC, Bazylevich A, Gellerman G, Shpilberg O, Luboshits G, Firer MA.

J Nanobiotechnology. 2018 Mar 30;16(1):34. doi: 10.1186/s12951-018-0362-1.

4.

Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.

Hershkovitz-Rokah O, Geva P, Salmon-Divon M, Shpilberg O, Liberman-Aronov S.

Oncotarget. 2018 Jan 5;9(8):7928-7941. doi: 10.18632/oncotarget.23974. eCollection 2018 Jan 30.

5.

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O.

Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. Review.

PMID:
29359797
6.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223. No abstract available.

PMID:
28881919
7.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P.

Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5.

8.

18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.

Cohen YC, Berger T, Eshel L, Stern D, Bairey O, Raanani P, Shpilberg O.

Isr Med Assoc J. 2017 Jun;19(6):372-377.

9.

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.

Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.

Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.

PMID:
28589704
10.

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O.

Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.

PMID:
28336303
11.

Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.

Gafter-Gvili A, Gurion R, Raanani P, Shpilberg O, Vidal L.

Hematol Oncol. 2017 Dec;35(4):424-431. doi: 10.1002/hon.2350. Epub 2016 Oct 13. Review.

PMID:
27734524
12.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P.

J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.

PMID:
27354480
13.

High incidence of silent cerebral infarcts in adult patients with beta thalassemia major.

Pazgal I, Inbar E, Cohen M, Shpilberg O, Stark P.

Thromb Res. 2016 Aug;144:119-22. doi: 10.1016/j.thromres.2016.06.010. Epub 2016 Jun 14.

PMID:
27322087
14.

Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.

Vidal L, Gurion R, Ram R, Raanani P, Bairey O, Robak T, Gafter-Gvili A, Shpilberg O.

Leuk Lymphoma. 2016 Sep;57(9):2047-57. doi: 10.3109/10428194.2016.1154956. Epub 2016 Mar 16. Review.

PMID:
26980554
15.

High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia.

Shacham-Abulafia A, Itchaki G, Yeshurun M, Paul M, Peck A, Leader A, Shpilberg O, Ram R, Raanani P.

Acta Haematol. 2016;135(1):55-64. doi: 10.1159/000437131. Epub 2015 Oct 8.

PMID:
26443995
16.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C.

Bone Marrow Transplant. 2016 Jan;51(1):51-7. doi: 10.1038/bmt.2015.213. Epub 2015 Sep 14.

PMID:
26367239
17.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L.

Br J Haematol. 2015 Nov;171(3):344-54. doi: 10.1111/bjh.13582. Epub 2015 Jul 7.

18.

Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.

Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R.

Hematol Oncol. 2016 Dec;34(4):184-192. doi: 10.1002/hon.2233. Epub 2015 Jun 5.

PMID:
26052918
19.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.

Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, Israeli M, Levy-Assaraf M, Gruenewald T, Mechoulam R, Raanani P, Ram R.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5. doi: 10.1016/j.bbmt.2015.05.018. Epub 2015 May 30.

20.

CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.

Vidal L, Shpilberg O, Gurion R, Monsef I, Raanani P, Ram R, Gafter-Gvili A.

Acta Oncol. 2016;55(1):77-84. doi: 10.3109/0284186X.2015.1043025. Epub 2015 May 21. Review.

PMID:
25997705
21.

GFR in Patients with β-Thalassemia Major.

Milo G, Feige Gross Nevo R, Pazgal I, Gafter-Gvili A, Shpilberg O, Gafter U, Erman A, Stark P.

Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1350-6. doi: 10.2215/CJN.12181214. Epub 2015 May 11.

22.

Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation.

Cohen L, Yeshurun M, Shpilberg O, Ram R.

Transpl Infect Dis. 2015 Aug;17(4):510-7. doi: 10.1111/tid.12398. Epub 2015 Jun 18.

PMID:
25940504
23.

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.

Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Tarella C, Shpilberg O, Sender M, Salles G, Morschhauser F, Jaccard A, Lamy T, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Leithäuser M, Schlattmann P, Anagnostopoulos I, Raphael M, Riess H, Leblond V, Oertel S; German PTLD Study Group and the European PTLD Network.

Am J Transplant. 2015 Apr;15(4):1091-100. doi: 10.1111/ajt.13086. Epub 2015 Mar 3.

24.

Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.

Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.

Cancer Lett. 2015 May 1;360(2):245-56. doi: 10.1016/j.canlet.2015.02.031. Epub 2015 Feb 16.

PMID:
25697481
25.

High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?

Wolach O, Itchaki G, Bar-Natan M, Yeshurun M, Ram R, Herscovici C, Shpilberg O, Douer D, Tallman MS, Raanani P.

Hematol Oncol. 2016 Mar;34(1):28-35. doi: 10.1002/hon.2191. Epub 2015 Feb 17.

PMID:
25689584
26.

Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.

Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M, Shpilberg O.

Bone Marrow Transplant. 2015 May;50(5):706-14. doi: 10.1038/bmt.2014.325. Epub 2015 Feb 9. Review.

PMID:
25665042
27.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.

Br J Haematol. 2015 Mar;168(6):811-9. doi: 10.1111/bjh.13222. Epub 2014 Nov 17.

PMID:
25404094
28.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. doi: 10.1016/j.canlet.2014.10.006. Epub 2014 Oct 8.

PMID:
25305453
29.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Working Group.

Ann Oncol. 2014 Sep;25 Suppl 3:iii83-92. doi: 10.1093/annonc/mdu264. No abstract available.

30.

Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.

Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A.

Acta Oncol. 2014 Sep;53(9):1230-7. doi: 10.3109/0284186X.2014.934397. Epub 2014 Aug 27. Review.

PMID:
25162954
31.

First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.

Muchtar E, Ram R, Raanani P, Yeshurun M, Oniashvili N, Shpilberg O, Magen H.

Leuk Res. 2014 Dec;38(12):1401-6. doi: 10.1016/j.leukres.2014.06.024. Epub 2014 Jul 10.

PMID:
25060304
32.

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.

Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, Shpilberg O, Yeshurun M.

Leuk Res. 2014 Aug;38(8):913-7. doi: 10.1016/j.leukres.2014.05.020. Epub 2014 Jun 4.

PMID:
24939215
33.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ.

Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15. Erratum in: Blood. 2014 Aug 14;124(7):1201.

34.

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G.

J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12.

PMID:
24821885
35.

Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

Wolach O, Fraser A, Luchiansky M, Shapiro C, Radnay J, Shpilberg O, Lishner M, Lahav M.

Hematol Oncol. 2015 Mar;33(1):42-7. doi: 10.1002/hon.2127. Epub 2014 Jan 27.

PMID:
24470400
36.

Myeloma in scar tissue--an underreported phenomenon or an emerging entity in the novel agents' era? A single center series.

Muchtar E, Raanani P, Yeshurun M, Shpilberg O, Magen-Nativ H.

Acta Haematol. 2014;132(1):39-44. doi: 10.1159/000354830. Epub 2014 Jan 10.

PMID:
24434613
37.

Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.

Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A.

Leuk Res. 2014 Mar;38(3):352-60. doi: 10.1016/j.leukres.2013.12.012. Epub 2013 Dec 25. Review.

PMID:
24418750
38.

Limited positron emission tomography-computed tomography for restaging of lymphoma: a strategy for reducing radiation exposure among patients with early-stage curable lymphoma.

Wolach O, Bernstine H, Edel Y, Bairey O, Shpilberg O, Groshar D, Lahav M.

Acta Haematol. 2014;131(4):239-44. doi: 10.1159/000354842. Epub 2013 Dec 13.

PMID:
24355975
39.

Hodgkin lymphoma and hypothermia: case report and review of the literature.

Shepshelovich D, Shpilberg O, Lahav M, Itchaki G, Yakimov M, Raanani P, Cohen A.

Acta Haematol. 2014;131(4):227-30. doi: 10.1159/000355262. Epub 2013 Dec 5. Review.

PMID:
24335335
40.

Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P.

Am J Hematol. 2014 Mar;89(3):243-8. doi: 10.1002/ajh.23622.

41.

Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure.

Ovcharenko A, Granot G, Rokah OH, Park J, Shpilberg O, Raanani P.

Leuk Res. 2013 Dec;37(12):1729-36. doi: 10.1016/j.leukres.2013.10.005. Epub 2013 Oct 14.

PMID:
24176282
42.

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.

Shpilberg O, Jackisch C.

Br J Cancer. 2013 Sep 17;109(6):1556-61. doi: 10.1038/bjc.2013.371. Epub 2013 Sep 3.

43.

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.

Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R, Shpilberg O, Sulkes A, Stemmer SM.

PLoS One. 2013 Aug 26;8(8):e70044. doi: 10.1371/journal.pone.0070044. eCollection 2013. Review.

44.

The role of ¹⁸F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia.

Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, Yeshurun M, Tadmor B, Leibovici L, Shpilberg O, Groshar D.

Leuk Res. 2013 Sep;37(9):1057-62. doi: 10.1016/j.leukres.2013.06.025. Epub 2013 Jul 10.

PMID:
23849986
45.

Anthracycline-containing regimens for treatment of follicular lymphoma in adults.

Itchaki G, Gafter-Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M.

Cochrane Database Syst Rev. 2013 Jul 7;(7):CD008909. doi: 10.1002/14651858.CD008909.pub2. Review.

PMID:
23832787
46.

Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.

Muchtar E, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O.

Transplantation. 2013 Oct 15;96(7):657-63. doi: 10.1097/TP.0b013e31829b0718.

PMID:
23823652
47.

Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation.

Ram R, Yeshurun M, Farbman L, Herscovici C, Shpilberg O, Paul M.

J Infect. 2013 Sep;67(3):194-8. doi: 10.1016/j.jinf.2013.05.005. Epub 2013 May 23.

PMID:
23707844
48.

Trends and challenges in searching for HLA-matched unrelated donors in Israel.

Israeli M, Yeshurun M, Stein J, Ram R, Shpilberg O, Levi CL, Klein T.

Hum Immunol. 2013 Aug;74(8):942-5. doi: 10.1016/j.humimm.2013.04.012. Epub 2013 Apr 22.

PMID:
23619470
49.

Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay.

Israeli M, Klein T, Herscovici C, Ram R, Shpilberg O, Sredni B, Yeshurun M.

Clin Exp Immunol. 2013 Jun;172(3):475-82. doi: 10.1111/cei.12072.

50.

Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling.

Ovcharenko A, Granot G, Shpilberg O, Raanani P.

Leuk Res. 2013 Aug;37(8):956-62. doi: 10.1016/j.leukres.2013.03.010. Epub 2013 Apr 12.

PMID:
23587524

Supplemental Content

Loading ...
Support Center